Biotech
Editas Medicine
Editas Medicine raises $118M Follow-on Offering at $1.8B valuation
$118M
Total Raised
Follow-on Offering
Latest Round
2013
Founded
300+
Employees
11 Hurley Street, Cambridge, MA 02141
1 min read
Quick Facts
Valuation
$1.8B
Latest Round Size
$118M
Latest Round Date
October 2024
Editas Medicine: Follow-on Offering Funding Round
Editas Medicine has successfully raised $118M in Follow-on Offering funding, reaching a valuation of $1.8B.
Company Overview
Genome editing medicines
Funding Details
The Follow-on Offering round was led by Polaris Partners, with participation from Flagship Pioneering, Third Rock Ventures, Google Ventures.
Company Information
- Headquarters: 11 Hurley Street, Cambridge, MA 02141
- Founded: 2013
- Employees: 300+
- Category: Biotech
Investment
Editas Medicine plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Polaris Partners: Verified investor in Follow-on Offering
- Flagship Pioneering: Verified investor in Follow-on Offering
- Third Rock Ventures: Verified investor in Follow-on Offering
- Google Ventures: Verified investor in Follow-on Offering
Key Investors
Polaris Partners
Lead Investor
Verified investor in Follow-on Offering
Flagship Pioneering
Investor
Verified investor in Follow-on Offering
Third Rock Ventures
Investor
Verified investor in Follow-on Offering
Google Ventures
Investor
Verified investor in Follow-on Offering
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M